Essam M Alkhybari1,2, Mark F McEntee1, Patrick C Brennan1, Kathy P Willowson3, Peter L Kench1,4. 1. Faculty of Health Sciences, Discipline of Medical Radiation Science, The University of Sydney, Sydney, New South Wales, Australia. 2. Faculty of Applied Medical Sciences, Department of Radiology and Medical Imaging, Prince Sattam Bin Abdulaziz University, Al Kharj, Saudi Arabia. 3. The University of Sydney, Institute of Medical Physics, Sydney, New South Wales, Australia. 4. The University of Sydney, Brain, Mind Research Institute, Sydney, New South Wales, Australia.
Abstract
INTRODUCTION: The aim of this work is to report diagnostic reference levels (DRLs) for hybrid positron emission tomography and x-ray computed tomography (PET/CT) exams in Australia (AU) for Queensland (QLD) and Western Australia (WA) (AU QLD/WA) and New Zealand (NZ). METHODS: Two-structured booklets were designed to collect dose information, patient demographics, equipment details and acquisition protocols for fluoride-18 fluorodeoxyglucose (18 F-FDG) PET/CT procedures, and any additional diagnostic CT routinely performed as part of 18 F-FDG whole-body examination. The DRL was reported based on the 75th percentile and achievable dose for 18 F-FDG, CT dose index volume (CTDIvol ) and dose length product (DLP). The effective dose and total effective dose was reported for 18 F-FDG whole-body PET/CT examination. Also, the effective dose was reported separately for identified additional diagnostic CT. RESULTS: The findings of this study show that the current DRL for 18 F-FDG in AU QLD/WA and NZ was 333.75 MBq and 332.87 MBq, respectively. The reported AU QLD/WA CTDIvol and DLP associated with 18 F-FDG whole-body PET/CT examinations from vertex to thigh (VT) was 4.41 mGy and 474 mGy.cm. In NZ, the reported VT CTDIvol and DLP was 13.07 mGy and 1319.05 mGy.cm. The effective dose for 18 F-FDG and CT component was 5.6 mSv and 4.7 mSv for AU QLD/WA. For NZ, the effective dose was 5.7 mSv and 10.9 mSv for 18 F-FDG and CT component. The total effective dose delivered from the 18 F-FDG whole-body scan from the AU QLD/WA PET/CT centres (10.44 mSv) were lower than the radiation doses delivered from the NZ (16.65 mSv). CONCLUSIONS: The current DRLs were proposed for AU QLD/WA and NZ for 18 F-FDG whole-body PET/CT examinations. Variations existed in the current practice of AU QLD/WA and NZ PET/CT examinations. There is a need to optimize the radiation doses delivered from PET/CT examinations.
INTRODUCTION: The aim of this work is to report diagnostic reference levels (DRLs) for hybrid positron emission tomography and x-ray computed tomography (PET/CT) exams in Australia (AU) for Queensland (QLD) and Western Australia (WA) (AU QLD/WA) and New Zealand (NZ). METHODS: Two-structured booklets were designed to collect dose information, patient demographics, equipment details and acquisition protocols for fluoride-18 fluorodeoxyglucose (18 F-FDG) PET/CT procedures, and any additional diagnostic CT routinely performed as part of 18 F-FDG whole-body examination. The DRL was reported based on the 75th percentile and achievable dose for 18 F-FDG, CT dose index volume (CTDIvol ) and dose length product (DLP). The effective dose and total effective dose was reported for 18 F-FDG whole-body PET/CT examination. Also, the effective dose was reported separately for identified additional diagnostic CT. RESULTS: The findings of this study show that the current DRL for 18 F-FDG in AU QLD/WA and NZ was 333.75 MBq and 332.87 MBq, respectively. The reported AU QLD/WA CTDIvol and DLP associated with 18 F-FDG whole-body PET/CT examinations from vertex to thigh (VT) was 4.41 mGy and 474 mGy.cm. In NZ, the reported VT CTDIvol and DLP was 13.07 mGy and 1319.05 mGy.cm. The effective dose for 18 F-FDG and CT component was 5.6 mSv and 4.7 mSv for AU QLD/WA. For NZ, the effective dose was 5.7 mSv and 10.9 mSv for 18 F-FDG and CT component. The total effective dose delivered from the 18 F-FDG whole-body scan from the AU QLD/WA PET/CT centres (10.44 mSv) were lower than the radiation doses delivered from the NZ (16.65 mSv). CONCLUSIONS: The current DRLs were proposed for AU QLD/WA and NZ for 18 F-FDG whole-body PET/CT examinations. Variations existed in the current practice of AU QLD/WA and NZ PET/CT examinations. There is a need to optimize the radiation doses delivered from PET/CT examinations.
Authors: G L Poli; L Torres; M Coca; M Veselinovic; M Lassmann; H Delis; F Fahey Journal: Eur J Nucl Med Mol Imaging Date: 2019-12-08 Impact factor: 9.236
Authors: Natalie A Bebbington; Bryan T Haddock; Henrik Bertilsson; Eero Hippeläinen; Ellen M Husby; Virpi I Tunninen; Marcus Söderberg Journal: EJNMMI Phys Date: 2019-12-16